8-K: Traws Pharma Announces Full Year 2024 Results and Highlights Tivoxavir Marboxil's Potential for Bird Flu Treatment

Traws Pharma reports positive data supporting tivoxavir marboxil as a single-dose therapeutic agent for bird flu, ongoing FDA interaction for potential accelerated approval, and a cash runway into Q1 2026.

Summary

• Traws Pharma reported its full-year 2024 financial results and provided business highlights, focusing on its lead product candidate, tivoxavir marboxil (TXM), for bird flu and ratutrelvir for COVID-19.
• The company's cash, cash equivalents, and short-term investments were approximately $21.3 million as of December 31, 2024, expected to fund operations into Q1 2026.
• Research and development expenses for 2024 totaled $12.8 million, an increase from $11.4 million in 2023.
• General and administrative expenses for 2024 were $12.3 million, compared to $9.1 million in 2023.
• The net loss for 2024 was $166.5 million, driven by acquired in-process research and development expense of $117.5 million and warrant expense of $24.4 million.
• Traws Pharma had 5,073,790 shares of common stock outstanding as of March 26, 2025, reflecting the issuance of 3.9 million shares related to the December 31, 2024 financing.
• Tivoxavir marboxil (TXM) has shown significant antiviral activity in three animal models and positive Phase 1 data, supporting its potential as a single-dose therapeutic agent for bird flu.
• The company is in ongoing interaction with the FDA to align on a path forward for tivoxavir marboxil, including potential accelerated approval utilizing the Animal Rule.
• Ratutrelvir, a COVID-19 candidate, has shown potential as a treatment for COVID-19 and was presented at ICAR 2025.
• The company plans to provide an update on FDA discussions regarding the Animal Rule in Q2 2025 and submit a pre-IND meeting request to engage with the FDA to understand long COVID endpoints in Q2 2025.

Sentiment

Score: 7

Explanation: The document presents a mix of positive clinical data and financial results, balanced by a significant net loss and a CEO transition. The focus on addressing critical health threats and the potential for accelerated approval contribute to a moderately positive outlook.

Positives

• Tivoxavir marboxil (TXM) shows potential as a single-dose treatment for bird flu, supported by preclinical and Phase 1 data.
• TXM demonstrated a potent resistance profile and robust antiviral activity in three validated flu models.
• The company completed a financing in December, raising $20 million in gross proceeds.
• Traws Pharma is interacting with the FDA regarding a potential accelerated path to approval for TXM under the Animal Rule.
• Ratutrelvir, the COVID-19 candidate, is being developed as a ritonavir-independent treatment.
• The company's cash runway extends into Q1 2026.
• Positive data was presented at ICAR 2025 supporting the potential for ratutrelvir as a treatment for COVID-19.
• Tivoxavir marboxil (TXM) has demonstrated potent in vitro activity against a range of influenza strains in preclinical studies, including the highly pathogenic avian flu H5N1 (bird flu).

Negatives

• The company reported a significant net loss of $166.5 million for 2024, primarily due to acquired in-process research and development expense and warrant expense.
• General and administrative expenses increased by $3.2 million compared to the previous year, primarily attributable to an increase in consulting fees in connection with seeking strategic alternatives.
• Werner Cautreels, PhD, Chief Executive Officer (CEO), is retiring, effective on or about the close of business on March 31, 2025.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including the success and timing of clinical trials, collaborations, market conditions, and regulatory requirements.
• The extent of the spread and threat of bird flu and the ongoing need for improved therapy to reduce the frequency of clinical rebound and the concomitant risk for long COVID are uncertain.
• The company's ability to obtain sufficient additional capital to continue to advance its product candidates and operate its business is a risk.
• Uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom are risks.
• Risks related to the failure to realize any value from product candidates currently being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market exist.
• Uncertainties in retaining key personnel, including the executive team and directors, are a risk.
• Risks may stem from changes in the regulatory and/or political landscape.
• Risks are associated with the possible failure to realize certain anticipated benefits of Traws' 2024 merger with Trawsfynydd Therapeutics, Inc., including with respect to future financial and operating results.

Future Outlook

Traws Pharma anticipates providing an update on FDA discussions regarding the Animal Rule in Q2 2025 and submitting a pre-IND meeting request to engage with the FDA to understand long COVID endpoints in Q2 2025. The company believes its cash and cash equivalents will be sufficient to support ongoing operations into Q1 2026.

Management Comments

• 'I believe Traws made outstanding progress over the last year. We re-defined our focus -to treat critical threats to human health from respiratory diseases -with bird flu as our top priority,' said Werner Cautreels, PhD, Chief Executive Officer for Traws Pharma.
• Werner Cautreels stated that the company presented preclinical data demonstrating TXM's potent resistance profile, robust antiviral activity in three validated flu models, plus positive pharmacokinetic results from a Phase 1 study in healthy volunteers.
• Werner Cautreels noted that the successful financing completed in December provided Traws with $20 million in gross proceeds and complemented the investor base with the addition of new top-tier institutional health care investors.
• Dr. Cautreels stated that the company plans to review the ongoing need for improved COVID therapy to reduce the frequency of clinical rebound and the concomitant risk for long COVID, the opportunity for ratutrelvir, and next steps for both programs.

Industry Context

The announcement highlights the increasing concern over bird flu's pandemic potential and the need for improved COVID-19 therapies, aligning with broader industry efforts to address respiratory viral diseases. The focus on single-dose treatments and ritonavir-independent COVID-19 therapies reflects a trend towards more convenient and accessible antiviral options.

Comparison to Industry Standards

• Tivoxavir marboxil's single-dose approach for bird flu treatment aims to improve upon existing antiviral options that often require multi-day regimens.
• The development of ratutrelvir as a ritonavir-independent COVID-19 treatment seeks to address the limitations of drugs like PAXLOVID, which can have drug-drug interactions due to the ritonavir component.
• The company is seeking accelerated approval under the Animal Rule, a regulatory pathway used when human efficacy studies are not feasible, similar to strategies employed for other emerging infectious diseases.
• The company is comparing ratutrelvir to nirmatrelvir (the active ingredient in PAXLOVID) and ibuzatrelvir (being developed by Pfizer, Inc.)

Management Changes

Stakeholder Impact

• Shareholders: The announcement provides updates on the company's financial performance and drug development programs, which could influence investor sentiment.
• Employees: The CEO transition may impact employee morale and organizational structure.
• Patients: The development of tivoxavir marboxil and ratutrelvir could provide new treatment options for bird flu and COVID-19, respectively.
• Investors: The company's cash position and development plans are relevant to investors.

Next Steps

• Provide an update on FDA discussions regarding the Animal Rule in Q2 2025.
• Finalize formulation and CMC scale up for bird flu program.
• Finalize development plan in bird flu and move forward on path to approval.
• Submit a pre-IND meeting request to engage with the FDA to understand long COVID endpoints in Q2 2025.

Key Dates

Keywords

Tivoxavir marboxil, Ratutrelvir, Bird flu, COVID-19, Animal Rule, Antiviral, Clinical trials, FDA, Respiratory diseases, Pharmaceuticals